

### 1.3.1.1 DESCOVY PROPOSED PROFESSIONAL INFORMATION FOR MEDICINES FOR HUMAN USE

#### SCHEDULING STATUS

S4

#### WARNING:

LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS, INCLUDING FATAL CASES, HAVE BEEN REPORTED WITH THE USE OF NUCLEOSIDE ANALOGUES ALONE OR IN COMBINATION WITH OTHER ANITRETROVIRALS (SEE SECTION 4.4.)

DESCOVY IS NOT INDICATED FOR THE TREATMENT OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION AND THE SAFETY AND EFFICACY OF DESCOVY HAS NOT BEEN ESTABLISHED IN PATIENTS CO-INFECTED WITH HBV AND HIV. SEVERE ACUTE EXACERBATIONS OF HEPATITIS B HAVE BEEN REPORTED IN PATIENTS WHO ARE CO-INFECTED WITH HBV AND HIV AND HAVE DISCONTINUED TENOFOVIR AND EMTRICITABINE, WHICH ARE COMPONENTS OF DESCOVY. HEPATIC FUNCTION SHOULD BE MONITORED CLOSELY WITH BOTH CLINICAL AND LABORATORY FOLLOW-UP FOR AT LEAST SEVERAL MONTHS IN PATIENTS INFECTED WITH HBV WHO DISCONTINUE THE COMBINATION TABLET AND ARE CO-INFECTED WITH HIV AND HBV.

IF APPROPRIATE, INITIATION OF ANTI-HEPATITIS B THERAPY MAY BE WARRANTED (SEE SECTION 4.4,

#### 1 NAME OF THE MEDICINE

DESCOVY 200 mg/10 mg Film-coated Tablets

DESCOVY 200 mg/25 mg Film-coated Tablets

#### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 200 mg of emtricitabine and 11.2 mg tenofovir alafenamide hemifumarate equivalent to 10 mg of tenofovir alafenamide.

Each tablet contains 200 mg of emtricitabine and 28.0 mg tenofovir alafenamide hemifumarate equivalent to 25 mg of tenofovir alafenamide.

#### 3. PHARMACEUTICAL FORM

Film-coated tablet.

Grey, rectangular-shaped, film-coated tablet of dimensions 12,5 mm x 6,4 mm debossed with "GSI" on one side and "210" on the other side of the tablet.

Blue, rectangular-shaped, film-coated tablet of dimensions 12,5 mm x 6,4 mm debossed with “GSI” on one side and “225” on the other side of the tablet.

#### 4. CLINICAL PARTICULARS

##### 4.1 Therapeutic indications

Descovy is indicated in combination with other antiretroviral medicines for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1) (see sections 4.2 and 5.1).

##### 4.2 Posology and method of administration

Therapy should be initiated by a medical practitioner experienced in the management of HIV infection.

###### Posology

*Adults and adolescents aged 12 years and older, weighing at least 35 kg*

Descovy should be administered as shown in Table 1.

**Table 1: Dose of Descovy according to third agent in the HIV treatment regimen**

| Dose of Descovy              | Third medicine in HIV treatment regimen<br>(see section 4.5)   |
|------------------------------|--|
| Descovy 200/10 mg once daily | Atazanavir with ritonavir or cobicistat<br>Darunavir with ritonavir or cobicistat <sup>1</sup><br>Lopinavir with ritonavir |
| Descovy 200/25 mg once daily | Dolutegravir, efavirenz, maraviroc,<br>nevirapine, rilpivirine, raltegravir  |

Descovy 200/10 mg in combination with darunavir 800 mg and cobicistat 150 mg, administered as a fixed-dose combination tablet, was studied in treatment-naïve subjects.

If the patient misses a dose of Descovy within 18 hours of the time it is usually taken, the patient should take Descovy as soon as possible and resume the normal dosing schedule. If a patient misses a dose of Descovy by more than 18 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.

If the patient vomits within 1 hour of taking Descovy another tablet should be taken.

###### *Elderly*

No dose adjustment of Descovy is required in elderly patients (see sections 5.1 and 5.2).

### *Renal impairment*

No dose adjustment of Descovy is required in adults or adolescents (aged at least 12 years and of at least 35 kg body weight) with estimated creatinine clearance (CrCl)  $\geq$  30 mL/min. Descovy should be discontinued in patients with estimated CrCl that declines below 30 mL/min during treatment (see sections 4.4 and 5.2).

No dose adjustment of Descovy is required in adults with end stage renal disease (estimated CrCl < 15 mL/min) on chronic haemodialysis; however, Descovy should generally be avoided but may be used in these patients (see sections 4.4 and 5.2). On days of haemodialysis, Descovy should be administered after completion of haemodialysis treatment.

Descovy should be avoided in patients with estimated CrCl  $\geq$  15 mL/min and < 30 mL/min as the safety of Descovy has not been established in this population. Descovy should not be used in patients with CrCl < 15 mL/min who are not receiving haemodialysis (see section 4.4).

No data are available to make dose recommendations in children less than 18 years with end stage renal disease.

### *Hepatic impairment*

No dose adjustment of Descovy is required in patients with mild to moderate hepatic impairment. Descovy has not been studied in patients with severe hepatic impairment (Child-Pugh Class C); therefore, Descovy is not recommended for use in patients with severe hepatic impairment as no dose recommendations can be made (see sections 4.4 and 5.2).

### *Paediatric population*

The safety and efficacy of Descovy in children younger than 12 years of age, or weighing < 35 kg, have not been established. No data are available.

### Method of administration

Descovy should be taken orally, once daily with or without food (see section 5.2). The film-coated tablet should not be chewed, crushed, or split.

## **4.3 Contraindications**

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

#### **4.4 Special warnings and precautions for use**

While effective viral suppression with antiretroviral therapy has been proven to reduce the risk of sexual transmission or blood contamination, the risk of transmission remains present.

Precautions to prevent transmission should be taken in accordance with national guidelines.

#### **Patients co-infected with HIV and hepatitis B or C virus**

Patients with chronic hepatitis B or C treated with antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.

The safety and efficacy of Descovy in patients co-infected with HIV-1 and hepatitis C virus (HCV) have not been established.

Tenofovir alafenamide is active against hepatitis B virus (HBV). Discontinuation of Descovy therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis. Patients co-infected with HIV and HBV who discontinue Descovy should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment.

In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post treatment exacerbation of hepatitis may lead to hepatic decompensation.

#### **Liver disease**

Use of DESCOVY can result in hepatomegaly due to non-alcoholic fatty liver disease (hepatic steatosis). The safety and efficacy of DESCOVY has not been established in patients with significant underlying liver disorders/diseases. In case of concomitant antiviral therapy for hepatitis B or C, please also consult the Professional Information of these medicines. Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored. If there is evidence of worsening liver disease in such patients, temporary or permanent discontinuation of treatment must be considered.

#### **Weight and metabolic parameters**

An increase in weight and in levels of blood lipids (hyperlipidaemia) and glucose may occur during antiretroviral therapy. Such changes may in part be linked to disease control and life style. For lipids, there is in some cases evidence for a treatment effect, while for weight gain there is no strong evidence relating this to any particular treatment. For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines. Lipid disorders should be managed as clinically appropriate.

#### Mitochondrial dysfunction following exposure *in utero*

Nucleos(t)ide analogues have been demonstrated *in vitro* and *in vivo* to cause a variable degree of mitochondrial dysfunction/ damage. There have been reports of mitochondrial dysfunction in HIV negative infants exposed *in utero* and/or postnatally to nucleoside analogues.

Manifestations of

mitochondrial dysfunction include haematological disorders (anaemia, neutropenia), peripheral neuropathy and metabolic disorders (hyperlactataemia, lactic acidosis, hyperlipasaemia). Late onset neurological disorders have been reported (hypertonia, convulsion, abnormal behaviour). Whether such neurological disorders are transient or permanent is unknown. Possible mitochondrial dysfunction should be considered in any newborn/infant/child exposed *in utero* to nucleos(t)ide analogues, including HIV negative infants/children who present with severe clinical findings of unknown etiology, particularly neurologic findings. These babies/infants and children should have clinical and laboratory follow up and be fully investigated for possible mitochondrial dysfunction

#### Lactic acidosis:

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including emtricitabine, a component of DESCOVY, and tenofovir DF, another prodrug of tenofovir, alone or in combination with other antiretrovirals. Treatment with DESCOVY should be suspended in any individual who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).

Clinical features of lactic acidosis are non-specific and include nausea, vomiting, abdominal pain, dyspnoea, fatigue and weight loss.

In patients with suspicious symptoms or biochemistry, measure the venous lactate level (normal < 2mmol/L), and the serum bicarbonate and respond as follows:

- Lactate 2-5 mmol/L with minimum symptoms: switch to medicines that are less likely to cause lactic acidosis
  - Lactate 5-10 mmol/L with symptoms and/or with reduced standard bicarbonate. Stop NRTIs and change treatment option. Once the lactate has settled, use medicines that are less likely to cause lactic acidosis.
- Exclude other causes (e.g. sepsis, uraemia, diabetic keto acidosis, thyrotoxicosis/hyperthyroidism)
- Lactate > 10mmol/L. STOP all therapy (80% mortality)

The above values may not be applicable to paediatric patients.

Caution should be exercised when administering DESCOVY to patients with known risk factors for liver disease.

#### Immune Reactivation Syndrome (IRS) / Immune Reconstitution Inflammatory Syndrome (IRIS)

Immune Reactivation Syndrome (IRS) is an immunopathological response resulting from the rapid restoration of pathogen-specific immune responses to pre-existing antigens combined with immune dysregulation, which occurs shortly after starting combination antiretroviral therapy (CART). Typically, such reaction presents by paradoxical deterioration of opportunistic infections being treated or with unmasking of asymptomatic opportunistic disease, often with an atypical inflammatory presentation. IRS usually develops within the first 3 months of initiation of ART and occurs more commonly in patients with low CD4+ counts. Relevant examples include cytomegalovirus retinitis, generalised and/or focal mycobacterial and other infections, such as tuberculosis, cryptococcal meningitis and *Pneumocystis jirovecii* pneumonia. Appropriate treatment of the opportunistic disease(s) should be instituted or continued, and ART continued. Inflammatory manifestations generally subside after a few weeks. Severe cases may respond to glucocorticoids, but there is only limited evidence for this in patients with tuberculosis IRS.

Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable, and these events can occur many months after initiation of treatment.

#### Patients with HIV-1 harbouring mutations

Descovy should not be started in antiretroviral-experienced patients with HIV-1 harbouring the K65R mutation (see section 5.1).

#### Triple nucleoside therapy

There have been reports of a high rate of virological failure and of emergence of resistance at an early stage when tenofovir disoproxil was combined with lamivudine and abacavir as well as with lamivudine and didanosine as a once daily regimen. Therefore, the same problems may be seen if Descovy is administered with a third nucleoside analogue.

### Opportunistic infections

Patients receiving DESCOVY should be advised that they may continue to develop opportunistic infections and other complications of HIV infection, and therefore they should remain under close observation by healthcare professionals experienced in the treatment of patients with associated HIV disease. Regular monitoring of viral load and CD4 counts needs to be done.

### Osteonecrosis

Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to cART. Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.

### Nephrotoxicity

A potential risk of nephrotoxicity resulting from chronic exposure to low levels of tenofovir due to dosing with tenofovir alafenamide cannot be excluded (see section 5.3).

### Patients with end stage renal disease on chronic haemodialysis

Descovy should generally be avoided but may be used in adults with end stage renal disease (estimated CrCl < 15 ml/min) on chronic haemodialysis with close monitoring for the risks (see section 4.2). In a study of emtricitabine + tenofovir alafenamide in combination with elvitegravir + cobicistat as a fixed-dose combination tablet (E/C/F/TAF) in HIV-1 infected adults with end stage renal disease (estimated CrCl < 15 ml/min) on chronic haemodialysis, efficacy was maintained through 48 weeks but emtricitabine exposure was significantly higher than in patients with normal renal function. Although there were no new safety issues identified, the implications of increased emtricitabine exposure remain uncertain (see sections 4.8 and 5.2).

### Co-administration of other medicines

The co-administration of Descovy is not recommended with certain anticonvulsants (e.g., carbamazepine, oxcarbazepine, phenobarbitone and phenytoin), antimycobacterials (e.g., rifampicin, rifabutin, rifapentine), boceprevir, St. John's wort and HIV protease inhibitors (PIs) other than atazanavir, lopinavir and darunavir (see section 4.5).

Descovy should not be administered concomitantly with medicines containing tenofovir alafenamide, tenofovir disoproxil, emtricitabine, lamivudine or adefovir dipivoxil.

#### 4.5 Interaction with other medicines and other forms of interaction

Interaction studies have only been performed in adults.

##### Emtricitabine

*In vitro* and clinical pharmacokinetic interaction studies have shown that the potential for CYP-mediated interactions involving emtricitabine with other medicines is low. Co-administration of emtricitabine with medicines that are eliminated by active tubular secretion may increase concentrations of emtricitabine, and/or the co-administered medicine. Medicines that decrease renal function may increase concentrations of emtricitabine.

##### Tenofovir alafenamide

Tenofovir alafenamide is transported by P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Medicines that strongly affect P-gp and BCRP activity may lead to changes in tenofovir alafenamide absorption. Medicines that induce P-gp activity (e.g., rifampicin, rifabutin, carbamazepine, phenobarbital) are expected to decrease the absorption of tenofovir alafenamide, resulting in decreased plasma concentration of tenofovir alafenamide, which may lead to loss of therapeutic effect of Descovy and development of resistance. Co-administration of Descovy with other medicines that inhibit P-gp and BCRP activity (e.g., cobicistat, ritonavir, ciclosporin) is expected to increase the absorption and plasma concentration of tenofovir alafenamide. Based on data from an *in vitro* study, co-administration of tenofovir alafenamide and xanthine oxidase inhibitors (e.g., febuxostat) is not expected to increase systemic exposure to tenofovir *in vivo*.

Tenofovir alafenamide is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 *in vitro*. It is not an inhibitor or inducer of CYP3A *in vivo*. Tenofovir alafenamide is a substrate of OATP1B1 and OATP1B3 *in vitro*. The distribution of tenofovir alafenamide in the body may be affected by the activity of OATP1B1 and OATP1B3.

##### Other interactions

Tenofovir alafenamide is not an inhibitor of human uridine diphosphate glucuronosyltransferase (UGT) 1A1 *in vitro*. It is not known whether tenofovir alafenamide is an inhibitor of other UGT enzymes. Emtricitabine did not inhibit the glucuronidation reaction of a non-specific UGT substrate *in vitro*.

Interactions between the components of Descovy and potential co-administered medicines are listed in Table 2 (increase is indicated as “↑”, decrease as “↓”, no change as “↔”). The interactions described are based on studies conducted with Descovy, or the components of Descovy as individual agents and/or in combination, or are potential drug-drug interactions that may occur with Descovy.

**Table 2: Interactions between the individual components of Descovy and other medicines**

| Medicine by therapeutic areas <sup>1</sup> | Effects on medicine levels.<br>Mean percent change in AUC, C <sub>max</sub> ,<br>C <sub>min</sub> <sup>2</sup>  | Recommendation concerning co-administration with Descovy                    |
|--|---|---|
| <b>ANTI-INFECTIVES</b>                     |   |   |
| <b>Antifungals</b>                         |   |   |
| Ketoconazole<br>Itraconazole               | Interaction not studied with either of the components of Descovy.<br><br>Co-administration of ketoconazole or itraconazole, which are potent P-gp inhibitors, is expected to increase plasma concentrations of tenofovir alafenamide. | The recommended dose of Descovy is 200/10 mg once daily.                    |
| Fluconazole<br>Isavuconazole               | Interaction not studied with either of the components of Descovy.<br><br>Co-administration of fluconazole or isavuconazole may increase plasma concentrations of tenofovir alafenamide.   | Dose Descovy according to the concomitant antiretroviral (see section 4.2). |

| <b>Antimycobacterials</b>   |   |  |
|---|---|--|
| Rifabutin<br>Rifampicin<br>Rifapentine  | Interaction not studied with either of the components of Descovy.<br><br>Co-administration of rifampicin, rifabutin, and rifapentine, all of which are P-gp inducers, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance.   | Co-administration of Descovy and rifabutin rifampicin, or rifapentine is not recommended.  |
| <b>Anti-hepatitis C virus medicines</b>   |   |  |
| Ledipasvir (90 mg once daily)/sofosbuvir (400 mg once daily), emtricitabine (200 mg once daily)/tenofovir alafenamide (10 mg once daily) <sup>3</sup>   | Ledipasvir:<br>AUC: ↑ 79 %<br>C <sub>max</sub> : ↑ 65 %<br>C <sub>min</sub> : ↑ 93 %<br><br>Sofosbuvir:<br>AUC: ↑ 47 %<br>C <sub>max</sub> : ↑ 29 %<br><br>Sofosbuvir metabolite GS-331007:<br>AUC: ↑ 48 %<br>C <sub>max</sub> : ↔<br>C <sub>min</sub> : ↑ 66 %<br><br>Emtricitabine:<br>AUC: ↔<br>C <sub>max</sub> : ↔<br>C <sub>min</sub> : ↔<br><br>Tenofovir alafenamide:<br>AUC: ↔<br>C <sub>max</sub> : ↔ | No dose adjustment of ledipasvir or sofosbuvir is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2).                |
| Ledipasvir (90 mg once daily)/sofosbuvir (400 mg once daily), emtricitabine (200 mg once daily)/tenofovir alafenamide (25 mg once daily) <sup>4</sup>   | Ledipasvir:<br>AUC: ↔<br>C <sub>max</sub> : ↔<br>C <sub>min</sub> : ↔<br><br>Sofosbuvir:<br>AUC: ↔<br>C <sub>max</sub> : ↔<br><br>Sofosbuvir metabolite GS-331007:<br>AUC: ↔<br>C <sub>max</sub> : ↔<br>C <sub>min</sub> : ↔<br><br>Emtricitabine:<br>AUC: ↔<br>C <sub>max</sub> : ↔<br>C <sub>min</sub> : ↔<br><br>Tenofovir alafenamide:<br>AUC: ↑ 32 %<br>C <sub>max</sub> : ↔                               | No dose adjustment of ledipasvir or sofosbuvir is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2).                |
| Sofosbuvir (400 mg once daily)/velpatasvir (100 mg once daily), emtricitabine (200 mg once daily)/tenofovir alafenamide (10 mg once daily) <sup>3</sup> | Sofosbuvir:<br>AUC: ↑ 37 %<br>C <sub>max</sub> : ↔<br><br>Sofosbuvir metabolite GS-331007:<br>AUC: ↑ 48 %<br>C <sub>max</sub> : ↔<br>C <sub>min</sub> : ↑ 58 %<br><br>Velpatasvir:<br>AUC: ↑ 50 %   | No dose adjustment of sofosbuvir, velpatasvir or voxilaprevir is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2). |

|  |   |   |
|--|---|---|
|  | <p><math>C_{max}</math>: ↑ 30 %<br/> <math>C_{min}</math>: ↑ 60 %</p> <p>Emtricitabine:<br/> AUC: ↔<br/> <math>C_{max}</math>: ↔<br/> <math>C_{min}</math>: ↔</p> <p>Tenofovir alafenamide:<br/> AUC: ↔<br/> <math>C_{max}</math>: ↓ 20 % <sup>(39)</sup></p>   |   |
| <p>Sofosbuvir/velpatasvir/<br/> voxilaprevir<br/> (400 mg/100 mg/100 mg+100 mg once daily)<sup>7/</sup><br/> emtricitabine<br/> (200 mg once daily)/<br/> tenofovir<br/> alafenamide (10 mg once daily)<sup>3</sup></p>  | <p>Sofosbuvir:<br/> AUC: ↔<br/> <math>C_{max}</math>: ↑ 27 %</p> <p>Sofosbuvir metabolite GS-331007:<br/> AUC: ↑ 43 %<br/> <math>C_{max}</math>: ↔</p> <p>Velpatasvir:<br/> AUC: ↔<br/> <math>C_{min}</math>: ↑ 46 %<br/> <math>C_{max}</math>: ↔</p> <p>Voxilaprevir:<br/> AUC: ↑ 171 %<br/> <math>C_{min}</math>: ↑ 350 %<br/> <math>C_{max}</math>: ↑ 92 %</p> <p>Emtricitabine:<br/> AUC: ↔<br/> <math>C_{min}</math>: ↔<br/> <math>C_{max}</math>: ↔</p> <p>Tenofovir alafenamide:<br/> AUC: ↔<br/> <math>C_{max}</math>: ↓ 21 %</p> |   |
| <p>Sofosbuvir/velpatasvir/<br/> voxilaprevir<br/> (400 mg/100 mg/100 mg +100 mg once daily)<sup>7/</sup><br/> emtricitabine<br/> (200 mg once daily)/<br/> tenofovir<br/> alafenamide (25 mg once daily)<sup>4</sup></p> | <p>Sofosbuvir:<br/> AUC: ↔<br/> <math>C_{max}</math>: ↔</p> <p>Sofosbuvir metabolite GS-331007:<br/> AUC: ↔<br/> <math>C_{min}</math>: ↔</p> <p>Velpatasvir:<br/> AUC: ↔<br/> <math>C_{min}</math>: ↔<br/> <math>C_{max}</math>: ↔</p> <p>Voxilaprevir:<br/> AUC: ↔<br/> <math>C_{min}</math>: ↔<br/> <math>C_{max}</math>: ↔</p> <p>Emtricitabine:<br/> AUC: ↔<br/> <math>C_{min}</math>: ↔<br/> <math>C_{max}</math>: ↔</p> <p>Tenofovir alafenamide:<br/> AUC: ↑ 52 %<br/> <math>C_{max}</math>: ↑ 32 %</p>                            | <p>No dose adjustment of sofosbuvir, velpatasvir or voxilaprevir is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2).</p> |

| <b>ANTIRETROVIRALS</b>  |   |  |
|---|---|--|
| <b>HIV protease inhibitors</b>  |   |  |
| Atazanavir/cobicistat (300 mg/150 mg once daily), tenofovir alafenamide (10 mg)                     | <p>Tenofovir alafenamide:<br/> AUC: ↑ 75 %<br/> C<sub>max</sub>: ↑ 80 %</p> <p>Atazanavir:<br/> AUC: ↔<br/> C<sub>max</sub>: ↔<br/> C<sub>min</sub>: ↔</p>  | The recommended dose of Descovy is 200/10 mg once daily.   |
| Atazanavir/ritonavir (300/100 mg once daily), tenofovir alafenamide (10 mg)                         | <p>Tenofovir alafenamide:<br/> AUC: ↑ 91 %<br/> C<sub>max</sub>: ↑ 77 %</p> <p>Atazanavir:<br/> AUC: ↔<br/> C<sub>max</sub>: ↔<br/> C<sub>min</sub>: ↔</p>  | The recommended dose of Descovy is 200/10 mg once daily.   |
| Darunavir/cobicistat (800/150 mg once daily), tenofovir alafenamide (25 mg once daily) <sup>5</sup> | <p>Tenofovir alafenamide:<br/> AUC: ↔<br/> C<sub>max</sub>: ↔</p> <p>Tenofovir:<br/> AUC: ↑ 224 %<br/> C<sub>max</sub>: ↑ 216 %<br/> C<sub>min</sub>: ↑ 221 %</p> <p>Darunavir:<br/> AUC: ↔<br/> C<sub>max</sub>: ↔<br/> C<sub>min</sub>: ↔</p>       | The recommended dose of Descovy is 200/10 mg once daily.   |
| Darunavir/ritonavir (800/100 mg once daily), tenofovir alafenamide (10 mg once daily)               | <p>Tenofovir alafenamide:<br/> AUC: ↔<br/> C<sub>max</sub>: ↔</p> <p>Tenofovir:<br/> AUC: ↑ 105 %<br/> C<sub>max</sub>: ↑ 142 %</p> <p>Darunavir:<br/> AUC: ↔<br/> C<sub>max</sub>: ↔<br/> C<sub>min</sub>: ↔</p>                                     | The recommended dose of Descovy is 200/10 mg once daily.   |
| Lopinavir/ritonavir (800/200 mg once daily), tenofovir alafenamide (10 mg once daily)               | <p>Tenofovir alafenamide:<br/> AUC: ↑ 47 %<br/> C<sub>max</sub>: ↑ 119 %</p> <p>Lopinavir:<br/> AUC: ↔<br/> C<sub>max</sub>: ↔<br/> C<sub>min</sub>: ↔</p>  | The recommended dose of Descovy is 200/10 mg once daily.   |
| Tipranavir/ritonavir  | <p>Interaction not studied with either of the components of Descovy.</p> <p>Tipranavir/ritonavir results in P-gp induction. Tenofovir alafenamide exposure is expected to decrease when tipranavir/ritonavir is used in combination with Descovy.</p> | Co-administration with Descovy is not recommended.   |
| Other protease inhibitors   | Effect is unknown.  | There are no data available to make dosing recommendations for co-administration with other protease inhibitors. |

| <b>Other HIV antiretrovirals</b>   |   |   |
|--|---|---|
| Dolutegravir (50 mg once daily), tenofovir alafenamide (10 mg once daily) <sup>3</sup>   | Tenofovir alafenamide:<br>AUC: ↔<br>C <sub>max</sub> : ↔<br><br>Dolutegravir:<br>AUC: ↔<br>C <sub>max</sub> : ↔<br>C <sub>min</sub> : ↔   | The recommended dose of Descovy is 200/25 mg once daily.  |
| Rilpivirine (25 mg once daily), tenofovir alafenamide (25 mg once daily)   | Tenofovir alafenamide:<br>AUC: ↔<br>C <sub>max</sub> : ↔<br><br>Rilpivirine:<br>AUC: ↔<br>C <sub>max</sub> : ↔<br>C <sub>min</sub> : ↔  | The recommended dose of Descovy is 200/25 mg once daily.  |
| Efavirenz (600 mg once daily), tenofovir alafenamide (40 mg once daily) <sup>4</sup>   | Tenofovir alafenamide:<br>AUC: ↓ 14 %<br>C <sub>max</sub> : ↓ 22 %  | The recommended dose of Descovy is 200/25 mg once daily.  |
| Maraviroc<br>Nevirapine<br>Raltegravir   | Interaction not studied with either of the components of Descovy.<br><br>Tenofovir alafenamide exposure is not expected to be affected by maraviroc, nevirapine or raltegravir, nor is it expected to affect the metabolic and excretion pathways relevant to maraviroc, nevirapine or raltegravir.               | The recommended dose of Descovy is 200/25 mg once daily.  |
| <b>ANTICONVULSANTS</b>   |   |   |
| Oxcarbazepine<br>Phenobarbitone<br>Phenytoin   | Interaction not studied with either of the components of Descovy.<br><br>Co-administration of oxcarbazepine, phenobarbital, or phenytoin, all of which are P-gp inducers, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance. | Co-administration of Descovy and oxcarbazepine, Phenobarbitone or phenytoin is not recommended.                           |
| Carbamazepine (titrated from 100 mg to 300 mg twice a day), emtricitabine/tenofovir alafenamide (200 mg/25 mg once daily) <sup>5,6</sup> | Tenofovir alafenamide:<br>AUC: ↓ 55 %<br>C <sub>max</sub> : ↓ 57 %<br><br>Co-administration of carbamazepine, a P-gp inducer, decreases tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance.  | Co-administration of Descovy and carbamazepine is not recommended.  |
| <b>ANTIDEPRESSANTS</b>   |   |   |
| Sertraline (50 mg once daily), tenofovir alafenamide (10 mg once daily) <sup>3</sup>   | Tenofovir alafenamide:<br>AUC: ↔<br>C <sub>max</sub> : ↔<br><br>Sertraline:<br>AUC: ↑ 9 %<br>C <sub>max</sub> : ↑ 14 %  | No dose adjustment of sertraline is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2). |

| <b>HERBAL PRODUCTS</b>   |  |  |
|--|--|--|
| St. John's wort<br>( <i>Hypericum perforatum</i> )   | Interaction not studied with either of the components of Descovy.<br><br>Co-administration of St. John's wort, a P-gp inducer, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance. | Co-administration of Descovy with St. John's wort is not recommended.  |
| <b>IMMUNOSUPPRESSANTS</b>  |  |  |
| Ciclosporin  | Interaction not studied with either of the components of Descovy.<br><br>Co-administration of ciclosporin, a potent P-gp inhibitor, is expected to increase plasma concentrations of tenofovir alafenamide.  | The recommended dose of Descovy is 200/10 mg once daily.   |
| <b>ORAL CONTRACEPTIVES</b>   |  |  |
| Norgestimate<br>(0.180/0.215/0.250 mg once daily), ethinylestradiol (0.025 mg once daily), emtricitabine/tenofovir alafenamide (200/25 mg once daily) <sup>5</sup> | Norelgestromin:<br>AUC: ↔<br>C <sub>min</sub> : ↔<br>C <sub>max</sub> : ↔<br><br>Norgestrel:<br>AUC: ↔<br>C <sub>min</sub> : ↔<br>C <sub>max</sub> : ↔<br><br>Ethinylestradiol:<br>AUC: ↔<br>C <sub>min</sub> : ↔<br>C <sub>max</sub> : ↔                              | No dose adjustment of norgestimate/ethinylestradiol is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2). |
| <b>SEDATIVES/HYPNOTICS</b>   |  |  |
| Orally administered midazolam (2.5 mg single dose) tenofovir alafenamide (25 mg once daily)  | Midazolam:<br>AUC: ↔<br>C <sub>max</sub> : ↔   | No dose adjustment of midazolam is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2).                     |
| Intravenously administered midazolam (1 mg single dose) tenofovir alafenamide (25 mg once daily)   | Midazolam:<br>AUC: ↔<br>C <sub>max</sub> : ↔   |  |

1 When doses are provided, they are the doses used in clinical drug-drug interaction studies  
2 When data are available from drug-drug interaction studies.  
3 Study conducted with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fixed-dose combination tablet.  
4 Study conducted with emtricitabine/rilpivirine/tenofovir alafenamide fixed-dose combination tablet.  
5 Study conducted with Descovy.  
6 Emtricitabine/tenofovir alafenamide was taken with food in this study.  
7 Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in HCV-infected patients.

#### **4.6 Fertility, pregnancy and lactation**

##### Women of childbearing potential / contraception in males and females

The use of DESCOVY should be accompanied by the use of effective contraception.

##### Pregnancy

The use of DESCOVY is not recommended in pregnancy unless no other appropriate medicine that is known to be safe in pregnancy is available, not tolerated or has failed.

Data on pregnant women (more than 1,000 exposed outcomes) indicate no malformative nor foetal/neonatal toxicity associated with emtricitabine. Animal studies do not indicate direct or indirect harmful effects of emtricitabine with respect to fertility parameters, pregnancy, foetal development, parturition or postnatal development.

There are no or limited data (less than 300 pregnancy outcomes) from the use of tenofovir alafenamide in pregnant women.

Studies of tenofovir alafenamide in animals have shown no evidence of harmful effects on fertility parameters, pregnancy, or foetal development (see section 5.3).

Nucleos(t)ide analogues, as in Descovy, may impact on mitochondrial function to a variable degree. There have been reports of mitochondrial dysfunction in HIV negative infants exposed in utero and/or postnatally to nucleoside analogues. The main adverse reactions reported are haematological disorders (anaemia, neutropenia), peripheral neuropathy and metabolic disorders (hyperlactataemia, hyperlipasaemia). These events have often been transitory. Late onset neurological disorders have been reported (hypertonia, convulsion, abnormal behaviour). Whether such neurological disorders are transient or permanent is unknown. These findings should be considered and investigated for any baby/ infant/child exposed in utero to nucleos(t)ide analogues, who present with severe clinical findings of unknown etiology, particularly neurologic findings.

##### Breast-feeding

Descovy should not be used by women breast-feeding their babies as possible harm to their babies cannot be excluded.

Emtricitabine is excreted in human milk. In animal studies it has been shown that tenofovir is excreted in milk.

In order to avoid transmission of HIV to the infant it is recommended that HIV infected women do not breast-feed their infants under any circumstances.

### Fertility

There are no data on fertility from the use of Descovy in humans. In animal studies there were no effects of emtricitabine and tenofovir alafenamide on mating or fertility parameters (see section 5.3).

#### **4.7 Effects on ability to drive and use machines**

DESCOVY may affect the ability to drive and use machines. Patients should not drive and use machines until they know how treatment with DESCOVY affects them. Patients should be informed that dizziness and fatigue have been reported during treatment with Descovy.

#### **4.8 Undesirable effects**

##### Summary of the safety profile

Assessment of adverse reactions is based on safety data from across all Phase 2 and 3 studies in which 3,112 HIV-1 infected patients received medicines containing emtricitabine and tenofovir alafenamide and from post-marketing experience. In clinical studies of 866 treatment-naïve adult patients receiving emtricitabine and tenofovir alafenamide with elvitegravir and cobicistat as the fixed-dose combination tablet elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide (as fumarate) 10 mg (E/C/F/TAF) through 144 weeks, the most frequently reported adverse reactions were diarrhoea (7 %), nausea (11 %), and headache (6 %).

##### Tabulated summary of adverse reactions

The adverse reactions in Table 3 are listed by system organ class and frequency. Frequencies are defined as follows: very common ( $\geq 1/10$ ) common ( $\geq 1/100$  to  $< 1/10$ ) and uncommon ( $\geq 1/1,000$  to  $< 1/100$ )

**Table 3: Tabulated list of adverse reactions reported in Clinical Trials**

| Frequency   | Adverse reaction                                |
|---|---|
| <i>Blood and lymphatic system disorders</i>                 |   |
| Uncommon:   | anaemia <sup>2</sup>                            |
| <i>Psychiatric disorders</i>                                |   |
| Common:   | abnormal dreams                                 |
| <i>Nervous system disorders</i>                             |   |
| Common:   | headache, dizziness                             |
| <i>Gastrointestinal disorders</i>                           |   |
| Very common:  | nausea  |
| Common:   | diarrhoea, vomiting, abdominal pain, flatulence |
| Uncommon:   | dyspepsia                                       |
| <i>Skin and subcutaneous tissue disorders</i>               |   |
| Common:   | Rash  |
| <i>Musculoskeletal and connective tissue disorders</i>      |   |
| Uncommon:   | arthralgia                                      |
| <i>General disorders and administration site conditions</i> |   |
| Common:   | fatigue   |

<sup>1</sup> All adverse reactions were identified from clinical studies of F/TAF containing products. The frequencies were derived from Phase 3 E/C/F/TAF clinical studies in 866 treatment-naïve adult patients through 144 weeks of treatment (GS-US-292-0104 and GS-US-292-0111).

<sup>2</sup> This adverse reaction was not observed in the clinical studies of F/TAF-containing products but identified from clinical studies or post-marketing experience for emtricitabine when used with other antiretrovirals.

**Table 4: Tabulated list of Post marketing reported side effects**

| Adverse reaction                                  |
|---|
| <i>Blood and lymphatic system disorders</i>       |
| Anaemia <sup>1</sup>                              |
| <i>Skin and subcutaneous tissue disorders</i>     |
| Angioedema, <sup>2,3</sup> urticaria <sup>3</sup> |

<sup>1</sup> This adverse reaction was not observed in the clinical studies of F/TAF-containing products but identified from clinical studies or post-marketing experience for emtricitabine when used with other antiretrovirals.

<sup>2</sup> This adverse reaction was identified through post-marketing surveillance for emtricitabine- containing products.

<sup>3</sup> This adverse reaction was identified through post-marketing surveillance for tenofovir alafenamide-containing products

#### Description of selected adverse reactions

##### *Changes in lipid laboratory tests*

In studies in treatment-naïve patients, increases from baseline were observed for the fasting lipid parameters total cholesterol, direct low-density lipoprotein (LDL)- and high-density lipoprotein (HDL)-cholesterol, and triglycerides at Week 144. The median (Q1, Q3) change from baseline in total cholesterol to HDL-cholesterol ratio at Week 144 was 0.2 (-0,3, 0,7) in the E/C/F/TAF group.

In a study of virologically suppressed patients switching from emtricitabine/tenofovir disoproxil fumarate to Descovy while maintaining the third antiretroviral agent, increases from baseline were observed in the fasting lipid parameters total cholesterol, direct LDL cholesterol and triglycerides in the Descovy arm. None of the changes was considered clinically relevant.

### *Metabolic parameters*

Weight and levels of blood lipids and glucose may increase during Descovy therapy.

### Paediatric population

The safety of emtricitabine and tenofovir alafenamide was evaluated through 48 weeks in an open-label clinical study in which HIV-1 infected, treatment-naïve paediatric patients aged 12 to < 18 years received emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet. The safety profile of emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat in 50 adolescent patients was similar to that in adults (see section 5.1).

### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of DESCOVY is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare providers are asked to report any suspected adverse reactions to SAHPRA via the “6.04 Adverse Drug Reactions Reporting Form” found online under SAHPRA’s publications: <https://www.sahpra.org.za/Publications/Index/8>.

## **4.9 Overdose**

In overdose, side effects can be precipitated and/or be of increased severity.

If overdose occurs the patient must be monitored for evidence of toxicity (see section 4.8). Treatment of overdose with Descovy consists of general symptomatic and supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient.

Emtricitabine can be removed by haemodialysis, which removes approximately 30 % of the emtricitabine dose over a 3hour dialysis period starting within 1,5 hours of emtricitabine dosing. Tenofovir is efficiently removed by haemodialysis with an extraction coefficient of approximately 54 %. It is not known whether emtricitabine or tenofovir can be removed by peritoneal dialysis.

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Pharmacological classification: A.20.2.8 Antiviral Agents

Pharmacotherapeutic group: Antiviral for systemic use; antivirals for treatment of HIV infections, combinations. ATC code: J05AR17.

#### Mechanism of action

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and nucleoside analogue of 2'-deoxycytidine. Emtricitabine is phosphorylated by cellular enzymes to form emtricitabine triphosphate.

Emtricitabine triphosphate inhibits HIV replication through incorporation into viral deoxyribonucleic acid (DNA) by the HIV reverse transcriptase (RT), which results in DNA chain-termination. Emtricitabine has activity against HIV-1, HIV-2, and HBV.

Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI) and phosphoramidate prodrug of tenofovir (2'-deoxyadenosine monophosphate analogue). Tenofovir alafenamide is permeable into cells and due to increased plasma stability and intracellular activation through hydrolysis by cathepsin A, tenofovir alafenamide is more efficient than tenofovir disoproxil fumarate in concentrating tenofovir in peripheral blood mononuclear cells (PBMCs) or HIV target cells including lymphocytes and macrophages. Intracellular tenofovir is subsequently phosphorylated to the pharmacologically active metabolite tenofovir diphosphate. Tenofovir diphosphate inhibits HIV replication through incorporation into viral DNA by the HIV RT, which results in DNA chain-termination.

Tenofovir has activity against HIV-1, HIV-2 and HBV.

#### Antiviral activity *in vitro*

Emtricitabine and tenofovir alafenamide demonstrated synergistic antiviral activity in cell culture.

No antagonism was observed with emtricitabine or tenofovir alafenamide when combined with other antiretroviral agents.

The antiviral activity of emtricitabine against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, the MAGI CCR5 cell line, and PBMCs. The 50 % effective concentration (EC<sub>50</sub>) values for emtricitabine were in the range of 0,0013 to 0,64 µm. Emtricitabine displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, and G (EC<sub>50</sub> values ranged from 0,007 to 0,075 µm) and showed strain specific activity against HIV-2 (EC<sub>50</sub> values ranged from 0,007 to 1,5 µm).

The antiviral activity of tenofovir alafenamide against laboratory and clinical isolates of HIV-1 subtype B was assessed in lymphoblastoid cell lines, PBMCs, primary monocyte/macrophage cells and CD4+T lymphocytes. The EC<sub>50</sub> values for tenofovir alafenamide were in the range of 2,0 to 14,7 nm. Tenofovir alafenamide displayed antiviral activity in cell culture against all HIV-1 groups (M, N, and O), including subtypes A, B, C, D, E, F, and G (EC<sub>50</sub> values ranged from 0,10 to 12,0 nm) and showed strain specific activity against HIV-2 (EC<sub>50</sub> values ranged from 0,91 to 2,63 nm).

#### Resistance

##### *In vitro*

Reduced susceptibility to emtricitabine is associated with M184V/I mutations in HIV-1 RT.

HIV-1 isolates with reduced susceptibility to tenofovir alafenamide express a K65R mutation in HIV-1 RT; in addition, a K70E mutation in HIV-1 RT has been transiently observed.

### *In treatment-naïve patients*

In a pooled analysis of antiretroviral-naïve patients receiving emtricitabine and tenofovir alafenamide (10 mg) given with elvitegravir and cobicistat as a fixed-dose combination tablet in Phase 3 studies GS-US-292-0104 and GS-US-292-0111, genotyping was performed on plasma HIV-1 isolates from all patients with HIV-1 RNA  $\geq$  400 copies/ml at confirmed virological failure, at Week 144, or at the time of early study drug discontinuation. Through Week 144, the development of one or more primary emtricitabine, tenofovir alafenamide, or elvitegravir resistance-associated mutations was observed in HIV-1 isolates from 12 of 22 patients with evaluable genotypic data from paired baseline and E/C/F/TAF treatment-failure isolates (12 of 866 patients [1,4 %]) compared with 12 of 20 treatment-failure isolates from patients with evaluable genotypic data in the E/C/F/TDF group (12 of 867 patients [1,4 %]). In the E/C/F/TAF group, the mutations that emerged were M184V/I (n = 11) and K65R/N (n = 2) in RT and T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1), and N155H (n = 2) in integrase. Of the HIV-1 isolates from 12 patients with resistance development in the E/C/F/TDF group, the mutations that emerged were M184V/I (n = 9), K65R/N (n = 4), and L210W (n = 1) in RT and E92Q/V (n = 4) and Q148R (n = 2), and N155H/S (n=3) in integrase. Most HIV-1 isolates from patients in both treatment groups who developed resistance mutations to elvitegravir in integrase also developed resistance mutations to emtricitabine in RT.

### *In patients co-infected with HIV and HBV*

In a clinical study of HIV virologically suppressed patients co-infected with chronic hepatitis B, who received emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed-dose combination tablet (E/C/F/TAF), for 48 weeks (GS-US-292-1249, n = 72), 2 patients qualified for resistance analysis. In these 2 patients, no amino acid substitutions associated with resistance to any of the components of E/C/F/TAF were identified in HIV-1 or HBV.

### *Cross-resistance in HIV-1 infected, treatment-naïve or virologically suppressed patients*

Emtricitabine-resistant viruses with the M184V/I substitution were cross-resistant to lamivudine, but retained sensitivity to didanosine, stavudine, tenofovir, and zidovudine.

The K65R and K70E mutations result in reduced susceptibility to abacavir, didanosine, lamivudine, emtricitabine, and tenofovir, but retain sensitivity to zidovudine.

Multinucleoside-resistant HIV-1 with a T69S double insertion mutation or with a Q151M mutation complex including K65R showed reduced susceptibility to tenofovir alafenamide.

### Clinical data

There are no efficacy and safety studies conducted in treatment-naïve patients with Descovy.

Clinical efficacy of Descovy was established from studies conducted with emtricitabine and tenofovir alafenamide when given with elvitegravir and cobicistat as the fixed-dose combination tablet E/C/F/TAF.

#### *HIV-1 infected, treatment-naïve patients*

In studies GS-US-292-0104 and GS-US-292-0111, patients were randomised in a 1:1 ratio to receive either emtricitabine 200 mg and tenofovir alafenamide 10 mg (n = 866) once daily or emtricitabine 200 mg + tenofovir disoproxil (as fumarate) 245 mg (n = 867) once daily, both given with elvitegravir 150 mg + cobicistat 150 mg as a fixed-dose combination tablet.

E/C/F/TAF demonstrated statistical superiority in achieving HIV-1 RNA < 50 copies/ml when compared to E/C/F/TDF at Week 144. The difference in percentage was 4,2 % (95 % CI: 0,6 % to 7,8 %).

The mean increase from baseline in CD4+ cell count was 230 cells/mm<sup>3</sup> in patients receiving E/C/F/TAF and 211 cells/mm<sup>3</sup> in patients receiving E/C/F/TDF (p = 0,024) at Week 48, and 326 cells/mm<sup>3</sup> in E/C/F/TAF-treated patients and 305 cells/mm<sup>3</sup> in E/C/F/TDF-treated patients (p = 0,06) at Week 144.

Clinical efficacy of Descovy in treatment-naïve patients was also established from a study conducted with emtricitabine and tenofovir alafenamide (10 mg) when given with darunavir (800 mg) and cobicistat as a fixed-dose combination tablet (D/C/F/TAF) in-Study GS-US-299-0102.

#### *HIV-1 infected virologically suppressed patients*

In Study GS-US-311-1089, the efficacy and safety of switching from emtricitabine/tenofovir disoproxil fumarate to Descovy while maintaining the third antiretroviral agent were evaluated in a randomised, double-blind study of virologically suppressed HIV-1 infected adults (n = 663).

In Study GS-US-311-1717, patients who were virologically suppressed (HIV-1 RNA < 50 copies/ml) on their abacavir/lamivudine containing regimen for at least 6 months were randomised in a 1:1 ratio to either switch to Descovy (N=280) while maintaining their third agent at baseline or stay on their baseline abacavir/lamivudine -containing regimen (N=276).

Virologic success rates at Week 48 were: Descovy Containing Regimen: 89,7 % (227 of 253 subjects); Abacavir/lamivudine Containing Regimen: 92,7 % (230 of 248 subjects). At Week 48, switching to a Descovy-containing regimen was non-inferior to staying on a baseline abacavir/lamivudine-containing regimen in maintaining HIV-1 RNA < 50 copies/ml.

*HIV-1 infected patients with mild to moderate renal impairment*

In Study GS-US-292-0112, the efficacy and safety of emtricitabine and tenofovir alafenamide were evaluated in an open-label clinical study in which 242 HIV-1 infected patients with mild to moderate renal impairment (eGFR<sub>CG</sub>: 30-69 ml/min) were switched to emtricitabine and tenofovir alafenamide (10 mg) given with elvitegravir and cobicistat as a fixed-dose combination tablet.

At Week 144, 83,1 % (197/237 patients) maintained HIV-1 RNA < 50 copies/ml after switching to emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat as a fixed-dose combination tablet.

In Study GS-US-292-1825, the efficacy and safety of emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed-dose combination tablet were evaluated in a single arm, open-label clinical study in which 55 HIV-1 infected adults with end stage renal disease (eGFR<sub>CG</sub> < 15 ml/min) on chronic haemodialysis for at least 6 months before switching to emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed-dose combination tablet.

At Week 48, 81,8 % (45/55 patients) maintained HIV-1 RNA < 50 copies/ml after switching to emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed-dose combination tablet. There were no clinically significant changes in fasting lipid laboratory tests in patients who switched.

*Patients co-infected with HIV and HBV*

In open-label Study GS-US-292-1249, the efficacy and safety of emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed-dose combination tablet (E/C/F/TAF), were evaluated in adult patients co-infected with HIV-1 and chronic hepatitis B. Sixty-nine of the 72 patients were on prior TDF-containing antiretroviral therapy. At the start of treatment with E/C/F/TAF, the 72 patients had been for at least 6 months with or without suppression of HBV DNA and had compensated liver function. Eighty-six percent of patients (62/72) were HBV suppressed (HBV DNA < 29 IU/ml) and 42 % (30/72) were HBeAg positive at baseline.

Of the patients who were HBeAg positive at baseline, 1/30 (3.3 %) achieved seroconversion to anti-HBe at Week 48. Of the patients who were HBsAg positive at baseline, 3/70 (4.3 %) achieved seroconversion to anti-HBs Week 48.

At Week 48, 92 % of patients (66/72) maintained HIV-1 RNA < 50 copies/ml after switching to emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed-dose combination tablet. The mean change from baseline in CD4+ cell count at Week 48 was -2 cells/mm<sup>3</sup>.

Ninety-two percent (66/72 patients) had HBV DNA < 29 IU/ml using missing = failure analysis at Week 48. Of the 62 patients who were HBV suppressed at baseline, 59 remained suppressed and 3 had missing data. Of the 10 patients who were not HBV suppressed at baseline (HBV DNA  $\geq$  29 IU/ml), 7 became suppressed, 2 remained detectable, and 1 had missing data.

There are limited clinical data on the use of E/C/F/TAF in HIV/HBV co-infected patients who are treatment-naïve.

### Paediatric population

In Study GS-US-292-0106, the efficacy, safety, and pharmacokinetics of emtricitabine and tenofovir alafenamide were evaluated in an open-label study in which 50 HIV-1 infected, treatment-naïve adolescents received emtricitabine and tenofovir alafenamide (10 mg) given with elvitegravir and cobicistat as a fixed-dose combination tablet. At baseline, median plasma HIV-1 RNA was 4,7 log<sub>10</sub> copies/ml, median CD4+ cell count was 456 cells/mm<sup>3</sup> (range: 95-1,110), and median CD4+ % was 23 % (range: 7-45 %). Overall, 22 % had baseline plasma HIV-1 RNA > 100,000 copies/ml. At 48 weeks, 92 % (46/50) achieved HIV-1 RNA < 50 copies/ml, similar to response rates in studies of treatment-naïve HIV-1 infected adults. The mean increase from baseline in CD4+ cell count at Week 48 was 224 cells/mm<sup>3</sup>. No emergent resistance to E/C/F/TAF was detected through Week 48.

## **5.2 Pharmacokinetic properties**

### Absorption

Emtricitabine is rapidly and extensively absorbed following oral administration with peak plasma concentrations occurring at 1 to 2 hours post-dose. Following multiple dose oral administration of emtricitabine to 20 HIV-1 infected subjects, the (mean  $\pm$  SD) steady state plasma emtricitabine peak concentrations (C<sub>max</sub>) were 1,8  $\pm$  0,7  $\mu$ g/ml and the area-under the plasma concentration-time curve over a 24-hour dosing interval (AUC) was 10,0  $\pm$  3,1  $\mu$ g•h/ml. The mean steady state plasma trough concentration at 24 hours post-dose was equal to or greater than the mean *in vitro* IC<sub>90</sub> value for anti-HIV-1 activity.

Emtricitabine systemic exposure was unaffected when emtricitabine was administered with food. Following administration of food in healthy subjects, peak plasma concentrations were observed approximately 1 hour post-dose for tenofovir alafenamide administered as F/TAF (25 mg) or E/C/F/TAF (10 mg). The mean C<sub>max</sub> and AUC<sub>last</sub>, (mean  $\pm$  SD) under fed conditions following a single 25 mg dose of tenofovir alafenamide administered in Descovy were 0,21  $\pm$  0,13  $\mu$ g/ml and 0,25  $\pm$  0,11  $\mu$ g•h/ml, respectively. The mean C<sub>max</sub> and AUC<sub>last</sub> following a single 10 mg dose of tenofovir alafenamide administered in E/C/F/TAF were 0,21  $\pm$  0,10  $\mu$ g/ml and 0,25  $\pm$  0,08  $\mu$ g•h/ml, respectively.

Relative to fasting conditions, the administration of tenofovir alafenamide with a high fat meal (~800 kcal, 50 % fat) resulted in a decrease in tenofovir alafenamide  $C_{max}$  (15-37 %) and an increase in  $AUC_{last}$  (17-77 %).

#### Distribution

*In vitro* binding of emtricitabine to human plasma proteins was < 4 % and independent of concentration over the range of 0.02-200 µg/ml. At peak plasma concentration, the mean plasma to blood drug concentration ratio was ~1,0 and the mean semen to plasma drug concentration ratio was ~4,0.

*In vitro* binding of tenofovir to human plasma proteins is < 0,7 % and is independent of concentration over the range of 0,01-25 µg/ml. *Ex vivo* binding of tenofovir alafenamide to human plasma proteins in samples collected during clinical studies was approximately 80 %.

#### Biotransformation

*In vitro* studies indicate that emtricitabine is not an inhibitor of human CYP enzymes. Following administration of [<sup>14</sup>C]-emtricitabine, complete recovery of the emtricitabine dose was achieved in urine (~86 %) and faeces (~14 %). Thirteen percent of the dose was recovered in the urine as three putative metabolites. The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3'-sulfoxide diastereomers (~9 % of dose) and conjugation with glucuronic acid to form 2'-O-glucuronide (~4 % of dose). No other metabolites were identifiable.

Metabolism is a major elimination pathway for tenofovir alafenamide in humans, accounting for > 80 % of an oral dose. *In vitro* studies have shown that tenofovir alafenamide is metabolised to tenofovir (major metabolite) by cathepsin A in PBMCs (including lymphocytes and other HIV target cells) and macrophages; and by carboxylesterase-1 in hepatocytes. *In vivo*, tenofovir alafenamide is hydrolysed within cells to form tenofovir (major metabolite), which is phosphorylated to the active metabolite tenofovir diphosphate. In human clinical studies, a 10 mg oral dose of tenofovir alafenamide (given with emtricitabine and elvitegravir and cobicistat) resulted in tenofovir diphosphate concentrations > 4-fold higher in PBMCs and > 90 % lower concentrations of tenofovir in plasma as compared to a 245 mg oral dose of tenofovir disoproxil (as fumarate) (given with emtricitabine and elvitegravir and cobicistat).

*In vitro*, tenofovir alafenamide is not metabolised by CYP1A2, CYP2C8, CYP2C9, CYP2C19, or CYP2D6. Tenofovir alafenamide is minimally metabolised by CYP3A4. Upon co-administration with the moderate CYP3A inducer probe efavirenz, tenofovir alafenamide exposure was not significantly affected. Following administration of tenofovir alafenamide, plasma [<sup>14</sup>C] -radioactivity showed a time-dependent profile with

tenofovir alafenamide as the most abundant species in the initial few hours and uric acid in the remaining period.

### Elimination

Emtricitabine is primarily excreted by the kidneys with complete recovery of the dose achieved in urine (approximately 86 %) and faeces (approximately 14 %). Thirteen percent of the emtricitabine dose was recovered in urine as three metabolites. The systemic clearance of emtricitabine averaged 307 ml/min. Following oral administration, the elimination half-life of emtricitabine is approximately 10 hours.

Renal excretion of intact tenofovir alafenamide is a minor pathway with < 1 % of the dose eliminated in urine. Tenofovir alafenamide is mainly eliminated following metabolism to tenofovir. Tenofovir alafenamide and tenofovir have a median plasma half-life of 0,51 and 32,37 hours, respectively. Tenofovir is renally eliminated by both glomerular filtration and active tubular secretion.

### Pharmacokinetics in special populations

#### *Age, gender, and ethnicity*

No clinically relevant pharmacokinetic differences due to age, gender or ethnicity have been identified for emtricitabine, or tenofovir alafenamide.

#### Paediatric population

Exposures of emtricitabine and tenofovir alafenamide (given with elvitegravir and cobicistat) achieved in 24 paediatric patients aged 12 to < 18 years who received emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat were similar to exposures achieved in treatment-naïve adults (Table 5).

**Table 5: Pharmacokinetics of emtricitabine and tenofovir alafenamide in antiretroviral-naïve adolescents and adults**

|  | Adolescents                  |                  |                  | Adults             |                  |                  |
|--|------------------------------|------------------|------------------|--------------------|------------------|------------------|
|  | FTC <sup>a</sup>             | TAF <sup>b</sup> | TFV <sup>b</sup> | FTC <sup>a</sup>   | TAF <sup>c</sup> | TFV <sup>c</sup> |
| <b>AUC<sub>tau</sub></b><br><b>(ng·h/ml)</b> | 14,424,4<br>(23,9)           | 242,8<br>(57,8)  | 275,8<br>(18,4)  | 11,714,1<br>(16,6) | 206,4<br>(71,8)  | 292,6<br>(27,4)  |
| <b>C<sub>max</sub></b><br><b>(ng/ml)</b>     | 2,265,0<br>(22,5)            | 121,7<br>(46,2)  | 14,6<br>(20,0)   | 2,056,3<br>(20,2)  | 162,2<br>(51,1)  | 15,2<br>(26,1)   |
| <b>C<sub>tau</sub></b><br><b>(ng/ml)</b>     | 102,4<br>(38,9) <sup>b</sup> | N/A              | 10,0<br>(19,6)   | 95,2<br>(46,7)     | N/A              | 10,6<br>(28,5)   |

E/C/F/TAF = elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate

FTC = emtricitabine; TAF = tenofovir alafenamide fumarate; TFV = tenofovir

N/A = not applicable

Data are presented as mean (%CV).

a n = 24 adolescents (GS-US-292-0106); n = 19 adults (GS-US-292-0102)

b n = 23 adolescents (GS-US-292-0106, population PK analysis)

c n = 539 (TAF) or 841 (TFV) adults (GS-US-292-0111 and GS-US-292-0104, population PK analysis)

### *Renal impairment*

No clinically relevant differences in tenofovir alafenamide, or tenofovir pharmacokinetics were observed between healthy subjects and patients with severe renal impairment (estimated CrCl  $\geq$  15 ml/min and  $<$  30 ml/min) in a Phase 1 study of tenofovir alafenamide. In a separate Phase 1 study of emtricitabine alone mean systemic emtricitabine exposure was higher in patients with severe renal impairment (estimated CrCl  $<$  30 ml/min) (33,7  $\mu\text{g}\cdot\text{h}/\text{ml}$ ) than in subjects with normal renal function (11,8  $\mu\text{g}\cdot\text{h}/\text{ml}$ ). The safety of emtricitabine and tenofovir alafenamide has not been established in patients with severe renal impairment (estimated CrCl  $\geq$  15 ml/min and  $<$  30 ml/min).

Exposures of emtricitabine and tenofovir in 12 patients with end stage renal disease (estimated CrCl  $<$  15 ml/min) on chronic haemodialysis who received emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet (E/C/F/TAF) were significantly higher than in patients with normal renal function. No clinically relevant differences in tenofovir alafenamide pharmacokinetics were observed in patients with end stage renal disease on chronic haemodialysis as compared to those with normal renal function.

There were no new safety issues identified in patients with end stage renal disease on chronic haemodialysis receiving emtricitabine and tenofovir alafenamide, in combination with elvitegravir and cobicistat as a fixed-dose combination tablet.

There are no pharmacokinetic data on emtricitabine or tenofovir alafenamide in patients with end stage renal disease (estimated CrCl  $<$  15 ml/min) not on chronic haemodialysis. The safety of emtricitabine and tenofovir alafenamide has not been established in these patients.

### *Hepatic impairment*

The pharmacokinetics of emtricitabine have not been studied in subjects with hepatic impairment; however, emtricitabine is not significantly metabolised by liver enzymes, so the impact of liver impairment should be limited.

Clinically relevant changes in the pharmacokinetics of tenofovir alafenamide or its metabolite tenofovir were not observed in patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, total plasma concentrations of tenofovir alafenamide and tenofovir are lower than those seen in subjects with normal hepatic function. When corrected for protein binding, unbound (free) plasma concentrations of tenofovir alafenamide in severe hepatic impairment and normal hepatic function are similar.

#### *Hepatitis B and/or hepatitis C virus co-infection*

The pharmacokinetics of emtricitabine and tenofovir alafenamide have not been fully evaluated in patients co-infected with HBV and/or HCV.

### **5.3 Preclinical safety data**

Non-clinical data on emtricitabine reveal no genotoxicity, carcinogenic potential, or toxicity to reproduction and development relevant to humans.

Non-clinical studies of tenofovir alafenamide in rats and dogs revealed bone and kidney as the primary target organs of toxicity. Bone toxicity was observed as reduced BMD. A minimal infiltration of histiocytes was observed in the eye of dogs at high exposures to tenofovir alafenamide.

Tenofovir alafenamide was not mutagenic or clastogenic.

Because there is a lower tenofovir exposure in rats and mice after the administration of tenofovir alafenamide compared to tenofovir disoproxil fumarate, carcinogenicity studies and a rat peri-postnatal study were conducted only with tenofovir disoproxil fumarate which revealed no relevant carcinogenic potential and toxicity to reproduction and development. Reproductive toxicity studies in rats and rabbits showed no effects on mating, fertility, pregnancy or foetal parameters. However, the viability index and weight of pups were reduced in a peri-postnatal toxicity study at maternally toxic doses.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

#### Tablet core

Microcrystalline cellulose

Croscarmellose sodium

Magnesium stearate

#### Film-coating

*DESCOVY 200mg/10mg*

Polyvinyl alcohol

Titanium dioxide

Macrogol 3350

Talc

Iron oxide black (E172)

*DESCOVY 200mg/25mg*

Polyvinyl alcohol

Titanium dioxide

Macrogol 3350

Talc

Indigo carmine aluminium lake (E132)

**6.2 Incompatibilities**

Not applicable

**6.3 Shelf-life**

36 months

**6.4 Special precautions for storage**

Store at or below 30 °C

Store in the original package in order to protect from moisture.

Keep the bottle tightly closed.

**6.5 Nature and contents of container**

High density polyethylene (HDPE) bottle with a polypropylene continuous-thread, child-resistant cap, lined with an induction activated aluminium foil liner containing 30 film-coated tablets. Each bottle contains silica gel desiccant and polyester coil.

The following pack sizes are available: outer cartons containing 1 bottle of 30 film-coated tablets

**6.6 Special precautions for disposal**

Any unused medicine or waste material should be disposed of in accordance with local requirements.

**7. HOLDER OF CERTIFICATE OF REGISTRATION**

Gilead Sciences South Africa (Pty) Ltd,

Ground Floor,

West Wing,

No. 6 Kikuyu Road,

Sunninghill Extension 56,

Johannesburg, 2191

**8        REGISTRATION NUMBERS**

To be allocated.

**9        DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

To be confirmed.

**10       DATE OF REVISION OF THE TEXT**

N/A